Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes

摘要

Most patients with breast cancer need anthracycline-based chemotherapy regimens in the adjuvant setting, and an increasing number of them receive taxanes either in this setting or as first-line therapy for metastatic breast cancer (MBC). However, no standard chemotherapy has been fully established for MBC patients pretreated with anthracycline and taxanes.